Abstracts tagged "big data and safety"

Abstract Number: 210 • 2017 ACR/ARHP Annual Meeting
Pharmacovigilance Surveillance of Autoimmune Diseases Induced By Biological Agents: A Review of 12013 Cases (aeBIOGEAS-SEMI Registry)
Soledad Retamozo^1,2,3, Manuel Ramos-Casals^4,5, Marta Pérez de Lis⁶, Alejandra Flores-Chavez^7,8,9, Sofia Arteaga^10,11, Celeste Galcerán-Chaves¹², Belchin Kostov¹³, Roberto Pérez-Alvarez⁶ and Pilar Brito-Zerón^2,14, ¹Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ³Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, ⁴Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁵Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain, ⁶Department of Internal Medicine, Hospital Alvaro Cunqueiro, Vigo, Vigo, Spain, ⁷Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ⁸Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ⁹Programa de Doctorado en Ciencias Médicas, Centro Universitario de Investigaciones Biomédicas (CUIB), Universidad de Colima, Colima, Mexico, Mexico, Mexico, ¹⁰Residente de Reumatologia II año, Universidad de Antioquia, Medellin, Colombia, Medellin, Colombia, ¹¹d) Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ¹²Neuroscience Clinical Institute, Hospital Clínic, Barcelona, Spain, Barcelona, Spain, ¹³Primary Care Research Group, IDIBAPS, Centre d’Assistència Primària ABS Les Corts, CAPSE, Barcelona, Barcelona, Spain, ¹⁴Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain
Background/Purpose: The increasing use of biological agents has been linked with the paradoxical development of autoimmune processes. The scenario has dramatically change in recent years…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].